SOCIOECONOMIC EVALUATION OF HEMOSTASEOLOG IC THERAPIES AND ANTICOAGULATION

Since hemostaseologic therapies have a great impact on the budget of p ublic health insurance companies, the therapy of hemophilia, prophylax is of thrombosis and thrombolysis should be evaluated in a socioeconom ic way. The substitution therapy in hemophilia is consuming a great de al of health care resources. The patients require an expensive, chroni c therapy which enables them to be integrated in a normal social life. A lot of patients get a prophylaxis against thrombosis. Anticoagulant s have to be valued with respect to their cost-effectivenes-relation. If thrombolysis is evaluated economically, one will have to consider c arefully the high letality of thrombosis, the savings for the preventi on of an operation and the high impact of this therapy on health care bills. The steady increase in health care costs emphasizes the necessi ty of health economics. Physicians should run socioeconomic evaluation s to prove the use of different medicines and therapies and to represe nt the clinical point of view and the part of the patients.